Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03776175 · ClinicalTrials.gov registry record · Phase 2
A Study To Assess Pharmacodynamics, Safety And Tolerability Of PF-05221304 And PF-06865571 Co-Administered For 6 Weeks In Adults With Non-Alcoholic Fatty Liver Disease.
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 99
- Enrollment target
NCT03776175 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 99 participants.
The verdict
NCT03776175, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 99 participants
- Enrollment target
Study Summary
This study is to assess the effect of PF 05221304 alone, PF 06865571 alone, the co administration of PF 05221304 and PF 06865571, or placebo on whole liver fat in subjects with NAFLD. In addition, this study will evaluate the safety and tolerability of co administration of PF 05221304 and PF 06865571 along with the effects on selected pharmacodynamics (PD)/exploratory parameters, compared to administration of PF 05221304 alone, PF 06865571 alone, and placebo in adults with NAFLD.
Interventions
- DRUG Placebo
- DRUG PF-05221304 Monotherapy
- DRUG PF-06865571 Monotherapy
- DRUG PF-05221304 and PF-06865571 Combination
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2019-01-04 |
| Est. Completion | 2019-10-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03776175
The ClinicalTrials.gov registry entry for NCT03776175 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT03776175 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03776175 about?
NCT03776175 is a clinical study titled "A Study To Assess Pharmacodynamics, Safety And Tolerability Of PF-05221304 And PF-06865571 Co-Administered For 6 Weeks In Adults With Non-Alcoholic Fatty Liver Disease.". This study is to assess the effect of PF 05221304 alone, PF 06865571 alone, the co administration of PF 05221304 and PF 06865571, or placebo on whole liver fat in subjects with NAFLD. In addition, this study will evaluate the safety and tolerability of co administration of PF 05221304 and PF 0686557...
What is the current status of trial NCT03776175?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 99 participants. The study started on 2019-01-04. Estimated completion is 2019-10-11.
What interventions are being tested in trial NCT03776175?
The interventions under investigation include: Placebo (DRUG), PF-05221304 Monotherapy (DRUG), PF-06865571 Monotherapy (DRUG), PF-05221304 and PF-06865571 Combination (DRUG).
Who is sponsoring clinical trial NCT03776175?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.